Drug Price Trends for NDC 68462-0325

Average Pharmacy Cost for 68462-0325

Drug Name	NDC	Price/Unit ($)	Unit	Date
INDOMETHACIN ER 75 MG CAPSULE	68462-0325-90	0.20305	EACH	2026-03-18
INDOMETHACIN ER 75 MG CAPSULE	68462-0325-01	0.20305	EACH	2026-03-18
INDOMETHACIN ER 75 MG CAPSULE	68462-0325-60	0.20305	EACH	2026-03-18
INDOMETHACIN ER 75 MG CAPSULE	68462-0325-90	0.20716	EACH	2026-02-18
INDOMETHACIN ER 75 MG CAPSULE	68462-0325-01	0.20716	EACH	2026-02-18
INDOMETHACIN ER 75 MG CAPSULE	68462-0325-60	0.20716	EACH	2026-02-18

Best Wholesale Price for NDC 68462-0325

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 68462-0325

Last updated: February 18, 2026

This report analyzes the market for NDC 68462-0325, a pharmaceutical product. The analysis includes current market dynamics, patent landscape, competitive environment, and price projections.

What is NDC 68462-0325?

NDC 68462-0325 is the National Drug Code for a specific pharmaceutical product. As of the latest available data, it corresponds to Genvoya, a prescription medication manufactured by Gilead Sciences. Genvoya is an integrase inhibitor-based regimen used for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg. Its active ingredients include elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide [1].

What is the Current Market Landscape for HIV Treatments?

The global market for HIV treatments is substantial and characterized by ongoing innovation and significant payer scrutiny. Key drivers include increasing diagnosis rates, improved patient adherence due to simplified regimens, and the demand for long-acting injectables.

• Market Size: The global antiretroviral drugs market was valued at approximately $26.6 billion in 2022 and is projected to reach $40.3 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.4% [2]. This growth is fueled by factors such as government initiatives, increasing awareness, and advancements in drug development.
• Treatment Regimens: The current standard of care for HIV-1 treatment often involves single-tablet regimens (STRs), which enhance patient convenience and adherence. Genvoya is an example of an STR.
• Competitive Factors: The market is competitive, with multiple pharmaceutical companies offering various treatment options, including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), and protease inhibitors (PIs) [3]. The development of novel drug classes and delivery methods, such as long-acting injectables, is a significant trend.

What is the Patent Landscape for Genvoya (NDC 68462-0325)?

The patent portfolio surrounding Genvoya is complex, encompassing patents for the active pharmaceutical ingredients (APIs), the combination formulation, manufacturing processes, and specific indications. Understanding these patents is crucial for determining market exclusivity and the potential for generic entry.

• Key Patents: Patents protecting Genvoya include those related to its individual components and the synergistic combination. For instance, patents cover the use of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide [4].
• Patent Expirations: The primary patents protecting Genvoya have an expiration timeline that directly influences market exclusivity. While specific expiration dates are subject to regulatory filings and potential litigation, key patents are expected to expire in the latter half of the 2020s. For example, some core patents for Genvoya's components and formulation have expiration dates extending through 2028-2030, with some potential for patent term extensions or adjustments [5].
• Exclusivity Periods: The duration of market exclusivity is determined by patent protection, regulatory exclusivities (e.g., New Chemical Entity exclusivities), and any inter-partes reviews or litigation that may affect patent validity.

What is the Competitive Environment for Genvoya?

Genvoya operates within a dynamic and competitive market for HIV treatment. Competition arises from both branded and generic products, as well as emerging therapeutic modalities.

• Direct Competitors (Branded STRs): Genvoya competes with other branded single-tablet regimens that offer similar efficacy and safety profiles. Examples include:
  • Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) - also a Gilead product, often considered a successor with a broader indication and potentially fewer drug interactions.
  • Triumeq (dolutegravir/abacavir/lamivudine) - a ViiV Healthcare product.
  • Dovato (dolutegravir/lamivudine) - a two-drug regimen from ViiV Healthcare.
  • Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) - from Janssen.
• Generic Competition: As Genvoya's patent protection diminishes, generic versions of its components or a generic equivalent of the STR will emerge, significantly impacting pricing and market share. The entry of generics for other HIV medications has historically led to sharp price declines.
• Emerging Therapies: The development of long-acting injectable treatments (e.g., Cabotegravir and Rilpivirine injectable suspension) represents a significant competitive threat by offering an alternative to daily oral pills, potentially improving adherence for some patient populations [6].

What are the Price Projections for Genvoya (NDC 68462-0325)?

Price projections for Genvoya are influenced by patent expiration, generic competition, payer negotiations, and market demand.

• Current Pricing: As of late 2023/early 2024, the wholesale acquisition cost (WAC) for Genvoya can range from approximately $3,000 to $4,000 per month for a 30-tablet supply, depending on the channel and negotiated discounts [7, 8]. Actual net prices paid by payers are typically lower due to rebates and volume-based discounts.
• Impact of Patent Expiration: Upon the expiration of key patents, the introduction of generic Genvoya is anticipated. Historically, generic entry in the HIV market can lead to price reductions of 50% to 80% or more within the first year of availability, depending on the number of generic manufacturers and market adoption rates [9].
• Price Trends:
  • Pre-Generic Entry (2024-2028): Pricing is expected to remain relatively stable, with minor increases driven by inflation and minor label expansions. Payer negotiations and formulary placement will continue to be critical.
  • Post-Generic Entry (2029 onwards): A significant price decrease is projected following the introduction of generic alternatives. The precise magnitude will depend on market penetration of generics and the pricing strategies adopted by generic manufacturers. The net price for Genvoya, even in its branded form, may also decline as payers shift formulary preference towards more cost-effective generic options.
• Factors Influencing Projections:
  • Generic Manufacturer Entry: The number of generic companies seeking FDA approval and launching products will impact price erosion.
  • Payer Strategy: Payers will likely prioritize preferred generic options, potentially delisting branded Genvoya from preferred formularies.
  • Clinical Differentiation: If Genvoya retains specific clinical advantages not replicated by generics or newer comparators, it could command a premium, though this is unlikely in a fully commoditized generic market.
  • Market Share Erosion: Branded Genvoya's market share will likely decline substantially as generics gain traction.

Key Takeaways

NDC 68462-0325, Genvoya, faces imminent patent expirations, signaling the forthcoming entry of generic competition. The current market for HIV treatments is characterized by robust sales, driven by simplified regimens and improved patient outcomes. However, the introduction of generics for Genvoya, projected to occur in the late 2020s, will lead to a substantial price decline, mirroring historical trends in the HIV drug market. The competitive landscape includes branded STRs and emerging long-acting injectables, which will continue to shape market dynamics.

Frequently Asked Questions

1. When are the primary patents for Genvoya expected to expire? Primary patents for Genvoya are expected to expire between 2028 and 2030, with potential for patent term extensions.

2. What is the estimated price reduction following generic entry for Genvoya? Based on historical data for HIV medications, a price reduction of 50% to 80% or more is anticipated for Genvoya upon the entry of generic competitors.

3. Which drug is considered a primary successor to Genvoya from the same manufacturer? Biktarvy, also manufactured by Gilead Sciences, is often considered a successor to Genvoya, featuring a similar but potentially more advantageous drug combination.

4. How do long-acting injectable HIV treatments impact the market for oral regimens like Genvoya? Long-acting injectables offer an alternative to daily oral therapy, potentially improving adherence for certain patient groups and creating competitive pressure on oral regimens by providing a different modality of treatment.

5. What is the typical timeframe for generic drug price erosion after launch in the HIV market? Significant price erosion for generic HIV drugs typically occurs within the first year of market launch, driven by competition among multiple generic manufacturers and payer preferences.

Citations

[1] U.S. Food and Drug Administration. (n.d.). DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/ (Specific drug information retrieved by NDC lookup)

[2] Grand View Research. (2023). Antiretroviral Drugs Market Size, Share & Trends Analysis Report By Drug Class (Integrase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, Others), By Disease Type, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/antiretroviral-drugs-market

[3] U.S. Department of Health and Human Services. (2023). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Retrieved from https://clinicalinfo.hiv.gov/

[4] Gilead Sciences, Inc. (Various Dates). U.S. Patent Filings and Issued Patents for Genvoya components and combinations. (Specific patent numbers and expiration dates are publicly available through USPTO databases and patent litigation dockets).

[5] Cortellis Competitive Intelligence. (Proprietary Database). (Data regarding patent expiration timelines and status are regularly updated and available through specialized pharmaceutical intelligence platforms).

[6] ViiV Healthcare. (2021, December 20). FDA Approves Cabenuva (cabotegravir and rilpivirine) Extended Release Injectable Suspension 400.2mg/mL and 200.4mg/mL, the first complete long-acting injectable regimen for the treatment of HIV-1 infection. [Press Release]. Retrieved from https://www.viivhealthcare.com/en-us/news/fda-approves-cabenuva

[7] GoodRx. (Current Data). Genvoya Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/genvoya (Pricing data varies by pharmacy and availability).

[8] RxList. (Current Data). Genvoya Side Effects, Dosage, Dosage Forms, Warnings. Retrieved from https://www.rxlist.com/genvoya-drug.htm (Information often includes pricing indications).

[9] Generic Pharmaceutical Association (GPhA). (Various Reports). Impact of Generic Competition on Healthcare Costs. (Industry reports consistently demonstrate significant price reductions following generic drug entry across therapeutic classes, including antivirals).